An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Paragon 28’s Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) has received FDA supplemental approval for its Patient Specific Talus Spacer, allowing it to be manufactured in titanium alloy with a titanium nitride coating. Initially approved on February 17, 2021, this implant is the only patient-specific total talus replacement authorized in the U.S., providing an alternative to traditional treatments for avascular necrosis of the ankle joint. CEO Albert DaCosta highlighted the expanded material options, which enhance the company’s Precision Ankle Solutions portfolio, including other innovative orthopedic products.
Positive
FDA approval for titanium alloy and nitride-coated Patient Specific Talus Spacer expands material options.
First and only FDA-approved patient-specific total talus replacement implant in the U.S.
ENGLEWOOD, Colo.--(BUSINESS WIRE)--
Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating.
The Patient Specific Talus Spacer was first approved on February 17, 2021, by the FDA under a Humanitarian Device Exemption for treatment of avascular necrosis of the ankle joint. Originally approved in cobalt chromium metal alloy, the implant is now available in titanium with a titanium nitride coating. The surgeon selects which material is best suited for his/her patient.
The Patient Specific Talus Spacer remains the first and only patient specific total talus replacement implant authorized for use in the United States. The implant is designed to replace the talus, an ankle bone that connects the leg and foot, providing patients access to a novel, joint-sparing alternative to amputation or traditional ankle fusion therapies.
Duke University Professor of Orthopaedic Surgery and Director of Digital Strategy & Innovation Selene Parekh, MD, MBA explained, “We are giving patients hope for a better quality of life with this surgery.”
Albert DaCosta, President and CEO of Paragon 28, commented, “P28 now has expanded material options available for the first and only FDA approved patient specific total talus replacement implant. P28 will continue to invest in patient specific solutions to help surgeons address unique and complex clinical challenges. We thank the FDA for a tremendous partnership during this process.”
The Patient Specific Talus Spacer bolsters Paragon 28's Precision Ankle Solutions product offering, which includes the APEX 3D™ Total Ankle Replacement System, MAVEN™ Patient Specific Guides, Gorilla® Ankle Fracture Plating System, Silverback® Ankle Fusion Plating System, and Phantom™ TTC Fusion Nail Systems. With this comprehensive portfolio, Paragon 28 provides its customers innovative ankle solutions for trauma, arthritis, and limb salvage.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28® is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent and reproducible.
What new approval did Paragon 28 receive regarding the Patient Specific Talus Spacer?
Paragon 28 received FDA supplemental approval to manufacture the Patient Specific Talus Spacer in titanium alloy with a titanium nitride coating.
When was the Patient Specific Talus Spacer first approved by the FDA?
The Patient Specific Talus Spacer was first approved on February 17, 2021.
What is the significance of the Patient Specific Talus Spacer in orthopedic treatment?
It is the only FDA-approved patient-specific total talus replacement implant in the U.S., providing an alternative to amputation or traditional ankle fusion.
How does the new titanium alloy enhance the Patient Specific Talus Spacer?
The new titanium alloy provides surgeons with more material options tailored to patient needs.
What other products are included in Paragon 28's Precision Ankle Solutions portfolio?
The portfolio includes the APEX 3D™ Total Ankle Replacement System, MAVEN™ Patient Specific Guides, and others.
